Optimizing Prostate Cancer Management: Leveraging PSMA Imaging to Enhance Treatment Strategies
 |
| Optimizing Prostate Cancer Management: Leveraging PSMA Imaging to Enhance Treatment Strategies Jason Efstathiou, MD, PhD; Brandon Mancini, MD, MBA, FACRO; Comron Hassanzadeh, MD, MPH; and Bridget Koontz, MD, FASTRO, discuss the evolving role of PSMA PET imaging in prostate cancer, examining its impact on diagnosis, disease staging, treatment decisions, and posttreatment assessment. They also review key clinical trial data, current guideline recommendations, and real-world applications of PSMA PET imaging in practice. Watch Now |
|
Featured Video |
.png?width=580&upscale=true&name=MarketingWS%20(3).png) |
| The Evolving Role of PSMA PET in Prostate Cancer Imaging and Management Panelists discuss how prospective randomized data, notably from Hofman et al (Lancet, 2020), demonstrate that PSMA PET-CT exhibits superior diagnostic accuracy compared with conventional imaging in detecting pelvic nodal and distant metastases in patients with high-risk prostate cancer. Conventional imaging techniques, such as CT and bone scans, often have lower sensitivity and specificity, potentially missing smaller or early metastatic lesions. In contrast, PSMA PET-CT offers enhanced sensitivity and specificity, leading to more precise staging and management decisions. Watch Now |